Direct pro-arrhythmogenic effects of angiotensin II can be suppressed by AT1 receptor blockade in human atrial myocardium

European Journal of Heart Failure

Volumn 10, Issue 12, 2008, Pages 1172-1176

  von Lewinski, Dirk ^a   Kockskämper, Jens ^a   Rübertus, Sven Ulrich ^b   Zhu, Danan ^b   Schmitto, Jan D ^b   Schöndube, Friedrich A ^b   Hasenfuss, Gerd ^b   Pieske, Burkert ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Angiotensin; Atrial fibrillation; Heart failure; Remodelling

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIAC GLYCOSIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IRBESARTAN; SARALASIN;

ADULT; AGED; ARRHYTHMOGENESIS; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ELECTROSTIMULATION; HEART ARRHYTHMIA; HEART ATRIUM; HEART ATRIUM APPENDAGE; HEART ATRIUM FIBRILLATION; HEART MUSCLE; HUMAN; HUMAN TISSUE; INCIDENCE; INOTROPISM; MUSCLE ISOMETRIC CONTRACTION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ATRIAL FIBRILLATION; CARDIOTONIC AGENTS; FEMALE; HEART; HEART ATRIA; HUMANS; INCIDENCE; ISOMETRIC CONTRACTION; MALE; MUSCLE, SKELETAL; MYOCARDIUM; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 56349152651     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2008.09.014     Document Type: Article

References (17)

1. Ahmed A., Thornton P., Perry G.J., Allman R.M., and DeLong J.F. Impact of atrial fibrillation on mortality and readmission in older adults hospitalized with heart failure. Eur J Heart Fail 6 4 (2004) 421-426
2. Goette A., Arndt M., Rocken C., et al. Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation 101 23 (2000) 2678-2681
3. Pieske B., Sutterlin M., Schmidt-Schweda S., et al. Diminished post-rest potentiation of contractile force in human dilated cardiomyopathy. Functional evidence for alterations in intracellular Ca2+ handling. J Clin Invest 98 3 (1996) 764-776
4. Wachtell K., Lehto M., Gerdts E., et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 45 5 (2005) 712-719
5. L'Allier P.L., Ducharme A., Keller P.F., Yu H., Guertin M.C., and Tardif J.C. Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. J Am Coll Cardiol 44 1 (2004) 159-164
6. Madrid A.H., Bueno M.G., Rebollo J.M., et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 106 3 (2002) 331-336
7. Ueng K.C., Tsai T.P., Yu W.C., et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 24 23 (2003) 2090-2098
8. Verheule S., Sato T., Everett T.t., et al. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1. Circ Res 94 11 (2004) 1458-1465
9. Hanna N., Cardin S., Leung T.K., and Nattel S. Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure. Cardiovasc Res 63 2 (2004) 236-244
10. Xiao H.D., Fuchs S., Campbell D.J., et al. Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death. Am J Pathol 165 3 (2004) 1019-1032
11. Li D., Shinagawa K., Pang L., et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 104 21 (2001) 2608-2614
12. Kistler P.M., Davidson N.C., Sanders P., et al. Absence of acute effects of angiotensin II on atrial electrophysiology in humans. J Am Coll Cardiol 45 1 (2005) 154-156
13. Dell'Italia L.J., Meng Q.C., Balcells E., et al. Compartmentalization of angiotensin II generation in the dog heart. Evidence for independent mechanisms in intravascular and interstitial spaces. J Clin Invest 100 2 (1997) 253-258
14. Nakashima H., Kumagai K., Urata H., Gondo N., Ideishi M., and Arakawa K. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 101 22 (2000) 2612-2617
15. Holubarsch C., Hasenfuss G., Schmidt-Schweda S., et al. Angiotensin I and II exert inotropic effects in atrial but not in ventricular human myocardium. An in vitro study under physiological experimental conditions. Circulation 88 3 (1993) 1228-1237
16. Gassanov N., Brandt M.C., Michels G., Lindner M., Er F., and Hoppe U.C. Angiotensin II-induced changes of calcium sparks and ionic currents in human atrial myocytes: potential role for early remodeling in atrial fibrillation. Cell Calcium 39 2 (2006) 175-186
17. Kockskämper J., Sigirci E., Rübertus S.U., and Pieske B. Endothelin-1 elicits arrhythmias in human atrium via modulation of intracellular calcium release. Circulation 110 17 (2004) 163